About Hangzhou Bio-Sincerity Pharma-Tech Company

The company focuses on the cutting edge of innovation, pioneering new models of innovative research and development through the construction of AI models with independent intellectual property rights, biochip application research, and the establishment of organoid banks. The business covers the full chain of drug development and industrialization services such as target design, target verification, compound preparation, pharmacological research, clinical trials, data management and statistics, patent design, global registration and reporting, CDMO/CMO, etc. The company is a comprehensive pharmaceutical R&D enterprise with technology development as the core, integrating innovative, full value chain, platformization and inclusive attributes. It mainly provides various pharmaceutical companies and pharmaceutical R&D investment enterprises: (1) pharmaceutical technology contract research and development services (CRO business); (2) R&D technology achievement transformation services; (3) customized R&D and production services (CDMO). After years of development and accumulation, the company has been widely recognized and praised by customers in the industry, and the company has become a highly competitive pharmaceutical research and development enterprise in China. Based on strong R&D strength and rich technological achievements, the company was rated as a national “high-tech enterprise”, “provincial high-tech enterprise research and development center”, and “Zhejiang High-growth Science and Technology Small and Medium Enterprise” and other honors.